RARA CRAFT DATABASE for FDA Medical Devices
510(k)K230041

FDA DEVICE FACTS

Spectrum IQ Infusion System with Dose IQ Safety Software

Baxter Healthcare Corporation

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEMarch 31, 2023PRODUCT CODEFRN

Indications for use

The Spectrum IQ Infusion System with Dose IQ Safety Software is intended to be used for the controlled administration of fluids. These may include pharmaceutical drugs, blood, and blood products. The intended routes of administration consist of the following clinically accepted routes: intravenous, arterial, subcutaneous, or epidural. The Spectrum IQ Infusion System with Dose IQ Safety Software is intended to be used in conjunction with legally marketed and compatible intravenous administration sets and medications provided by the user. The Spectrum IQ Infusion System with Dose IQ Safety Software is suitable for a variety of patient care environments such as, but not limited to, hospitals and outpatient care areas. The Spectrum IQ Infusion System with Dose IQ Safety Software is intended to reduce operator interaction through guided programming, including a way to automate the programming of infusion parameters and documentation of infusion therapies. This automation is intended to reduce pump programming errors and increase accuracy of infusion documentation. The Spectrum IQ Infusion System with Dose IQ Safety Software is intended to be used by trained healthcare professionals. BAXTER Confidential - Restricted: Do not distribute without prior approval TECHNOLOGICAL CHARACTERISTICS AND SUBSTANTIAL EQUIVALENCE: The intended use and function of the proposed device remains the same as the predicate device. The 510(k) premarket notification, K222048, of the predicate device was cleared on September 6, 2022. DISCUSSION OF NONCLINICAL TESTS: The scope of this notification is to update the algorithm and labeling related to the upstream occlusion alarm of the pump. Performance testing for the software was completed. Biocompatibility is not affected by this notification. The intended use and function of the proposed device is the same as the predicate device.

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 19, 2026